PH III: AZIMILIDE LONG TERM TREATMENT

房颤是临床上显著的持续性心动过速的最常见原因，并且在75岁以上的个体中发生高达12%。 发病率随着年龄的增长而增加。 此外，心房颤动是导致多达1/3的血栓栓塞性中风的原因。 可用的抗疟疾药物的选择及其疗效是有限的。因此，迫切需要开发在患有结构性心脏病的患者中安全并且不存在显著负性变时作用的新的抗心律失常剂。 一种这样的药物是Azimilide dihydrochloride，一种III类抗心律失常药，在试验剂量下具有非常弱的心动过缓作用。 本研究旨在验证这种新型抗肿瘤药物的长期安全性和有效性。

Atrial fibrillation is the most common cause of clinically significant sustained tachycardia and occurs in up to 12% of individuals that are over age 75. Incidence increases with each decade of life. Furthermore, atrial fibrillation is responsible for up to 1/3 of thromboembolic strokes. The selection of available antiarrhythmic drugs and their efficacy is limited. Accordingly, there is an important need for the development of new antiarrhythmic agents that are safe in patients with structural heart disease and are absence of significant negative chronotropic effects. One such drug is Azimilide dihydrochloride, a class III antiarrhythmic agent with very weak bradycardic effects at test doses. This study is to test the long-term safety and efficacy of this new antiarrhythmic drug.